These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32557601)

  • 1. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
    Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
    J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
    Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
    Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
    Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
    J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
    Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
    Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.
    Wang H; Yang Y; Chen Z; Fu L; Yu M; Jiang L; Wang C; Men L; Minto I; Yang D; Zhai Y
    Clin Transl Sci; 2024 Sep; 17(9):e70021. PubMed ID: 39228016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
    Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
    Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
    Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J; Li J; Wu J; Song Y; Li L; Zhang J; Dong R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1252. PubMed ID: 39073244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.